Holen Sie sich die Stockscreener-App
24.77
3.90%
0.93
Schlusskurs vom Vortag:
$23.84
Offen:
$24.07
24-Stunden-Volumen:
42.71M
Relative Volume:
1.48
Marktkapitalisierung:
$5.65B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
47.44
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+57.37%
1M Leistung:
+51.96%
6M Leistung:
-55.37%
1J Leistung:
-21.46%
1-Tages-Spanne:
$23.25
$24.82
1-Wochen-Bereich:
$20.97
$27.54
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.77 | 5.43B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims And Hers Health Weighs Eucalyptus Deal Against Growth And Valuation Risks - simplywall.st
Weekly Market Update: Stocks Slide as Financials, Consumer Cyclicals Fall - Morningstar
Hims & Hers Stock Skyrockets Amid Novo Nordisk Partnership - StocksToTrade
Hims Shares Set for Record Week as New Novo Pact Fuels Optimism - Bloomberg.com
Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution - Insider Monkey
Selling pressure pushes Hims & Hers Health stock lower in today's trading - Traders Union
Hims & Hers class action alleges semaglutide GLP-1 products falsely advertised - Class Action Lawsuits
Hims shares set for record week as Novo partnership fuels optimism - Modern Healthcare
Barclays Raises PT on Hims & Hers Health (HIMS) Stock - Yahoo Finance
Hims shares set for best week on record after new Novo Nordisk deal - Investing.com
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Hims & Hers Stock Jumps After Novo Nordisk Deal. What It Means for Drugmaker - TradingView
12 Most Shorted Stocks to Buy in 2026 - Insider Monkey
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications - MSN
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up - MedCity News
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - Yahoo Finance
Hims & Hers stock takes a major hit amid multiple investigations and target cuts - StocksToTrade
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking - Yahoo Finance
Hims And Hers Benefits Aims To Deepen Member Loyalty And Engagement - simplywall.st
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Hims & Hers Faces Investigation Amid Wegovy Sales Discontinuation - timothysykes.com
Hims & Hers Drops 29.4% Over Three Months: What’s the Best Strategy for This Stock? - Bitget
Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock? - The Globe and Mail
Hims & Hers Health hires Kathryn Beiser as chief communications officer - Medical Marketing and Media
Should You Chase the Rally in Hims & Hers Stock Today? - Barchart.com
Is Hims & Hers Really the Growth Stock to Buy That It Appears? - Yahoo Finance
Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably (NYSE:HIMS) - Seeking Alpha
Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket - Benzinga
Hims & Hers Health stock continues rally, rises 7% in premarket trading - MSN
Obesity Drugs Are Getting Easier and Cheaper to Find - Bloomberg
Hims & Hers Health (HIMS) Stock Up 7% Premarket Thursday, On Track for Best Week Ever - CoinCentral
Trending tickers: Nebius Group, Hims & Hers, BMW, Savills and On The Beach - Yahoo Finance UK
Hims & Hers (HIMS) soars 10.3% on analyst upgrades, new deal - MSN
Hims & Hers revamps GLP-1 strategy with Novo Nordisk - TipRanks
JPMorgan Chase & Co. Significantly Reduces Stake in Hims & Hers Health Inc. - GuruFocus
Hims & Hers (HIMS) Soars 10.3% on Analyst Upgrades, New Deal - Insider Monkey
A Look At Novo Nordisk’s Valuation After Hims & Hers GLP 1 Distribution Agreement - simplywall.st
Hims & Hers (NYSE: HIMS) revamps US GLP-1 weight-loss model - Stock Titan
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
Hims & Hers Hires Ex-Eli Lilly Communications Chief Amid Obesity Drug Strategy Shift - GuruFocus
Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War - FinancialContent
Hims & Hers C-suite shake-up, Stryker outage may be Iran-backed - Yahoo Finance
HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating Opportunity From New Products - Stocktwits
3 Big Reasons to Love Hims & Hers Health (HIMS) - Yahoo Finance
HIMS Jumps 14.5% Following Strong Market Interest - GuruFocus
Hims & Hers: The Novo Nordisk Deal Changes Everything (NYSE:HIMS) - Seeking Alpha
Hims & Hers Brings In Lilly Communications Veteran - GuruFocus
Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Barclays Raises Price Target for HIMS: Maintains Overweight Rati - GuruFocus
Hims & Hers Health Stock Is Surging Wednesday: What's Going On? - Benzinga
Hims & Hers Health (NYSE:HIMS) Shares Up 11.5% After Analyst Upgrade - MarketBeat
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):